"ID","7e-04","Description","8e-04","9e-04","0.001","0.0011","0.0012","0.0013","0.0014","0.0015","0.0016","0.0017","0.0018","0.0019","0.002","0.0021","0.0022","0.0023","0.0024","0.0025","0.0026","0.0027","0.0028"
"R-HSA-3899300",0.352059207074457,"SUMOylation of transcription cofactors",0.103215075747965,0.133209309541793,0.505757808872709,0.129831386541601,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69273",0.352059207074457,"Cyclin A/B1/B2 associated events during G2/M transition",0.128109416633944,0.266066835961489,0.505757808872709,0.325012742538874,0.36185792952012,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1592230",0.361628442393449,"Mitochondrial biogenesis",0.128109416633944,0.22301944357763,0.505757808872709,0.129831386541601,0.36185792952012,0.300297686482713,0.106324746821704,0.320466798440274,0.320466798440274,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,0.141192431845409,NA,NA,NA,NA,NA,NA,NA
"R-HSA-211945",0.361628442393449,"Phase I - Functionalization of compounds",0.128109416633944,0.404112818780624,0.505757808872709,0.355605895884058,0.36185792952012,0.582605465947298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2142753",0.361628442393449,"Arachidonic acid metabolism",0.128109416633944,0.175554186003043,0.505757808872709,0.65907669704264,0.580553949701949,0.553376238908736,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-194068",0.361628442393449,"Bile acid and bile salt metabolism",0.300268381096484,0.448077219878038,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-211859",0.406537454684087,"Biological oxidations",0.128109416633944,0.518975617478329,0.505757808872709,0.412360830577845,0.45893483786496,0.586610678167411,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9612973",0.456438548779482,"Autophagy",0.128109416633944,0.175554186003043,0.624982435852433,0.368903312637169,0.423748184638223,0.300297686482713,0.106324746821704,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,0.141192431845409,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2162123",0.506615127429457,"Synthesis of Prostaglandins (PG) and Thromboxanes (TX)",0.128109416633944,0.404112818780624,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1632852",0.582442601412297,"Macroautophagy",0.128109416633944,0.133209309541793,0.52260629047387,0.333723101231822,0.36185792952012,0.2964626986253,0.105101971371931,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,0.141192431845409,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1538133",0.604009831875893,"G0 and Early G1",0.168291506530234,0.602404733911731,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1474228",0.607271849402404,"Degradation of the extracellular matrix",0.474080922689698,0.632154668683662,0.670079175874988,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6804756",0.607271849402404,"Regulation of TP53 Activity through Phosphorylation",0.128109416633944,0.133209309541793,0.505757808872709,0.129831386541601,0.3371369955999,0.2964626986253,0.089667038957883,0.314120396090151,0.314120396090151,0.281794291118137,0.275102219677884,0.275102219677884,0.271399611045141,0.192318663728547,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6791312",0.607271849402404,"TP53 Regulates Transcription of Cell Cycle Genes",0.38224433575471,0.602404733911731,0.557657971652884,0.355605895884058,0.387670598741368,0.49751781997298,0.321019869345641,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8978868",0.607271849402404,"Fatty acid metabolism",0.38224433575471,0.448077219878038,0.670079175874988,0.790785221397698,0.701169351183535,0.582605465947298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168898",0.607271849402404,"Toll-like Receptor Cascades",0.38224433575471,0.602404733911731,0.505757808872709,0.368116648218107,0.550445999316192,0.649101852493996,0.491774536287782,0.400504103457655,0.400504103457655,0.35904564631684,0.324634520854464,0.324634520854464,0.305635238344384,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168643",0.607271849402404,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",0.638892966796051,0.642401185487417,0.505757808872709,0.325012742538874,0.496746453501941,0.553376238908736,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1989781",0.607271849402404,"PPARA activates gene expression",0.448944218623103,0.602404733911731,0.505757808872709,0.325012742538874,0.496746453501941,0.553376238908736,0.39132628290722,0.325042388920091,0.325042388920091,0.292849304840985,0.271737675382429,0.271737675382429,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-400206",0.607271849402404,"Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)",0.448944218623103,0.602404733911731,0.505757808872709,0.325012742538874,0.496746453501941,0.553376238908736,0.39132628290722,0.325042388920091,0.325042388920091,0.292849304840985,0.271737675382429,0.271737675382429,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2151201",0.607271849402404,"Transcriptional activation of mitochondrial biogenesis",0.422620292899137,0.607676706281574,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-381340",0.607271849402404,"Transcriptional regulation of white adipocyte differentiation",0.38224433575471,0.503941910247926,0.505757808872709,0.325012742538874,0.493948230420621,0.546029695356119,0.362277746159708,0.321386874472306,0.321386874472306,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-556833",0.607271849402404,"Metabolism of lipids",0.38224433575471,0.404112818780624,0.735981920956751,0.761769753297466,0.742074724526291,0.661519521946481,0.775448572536672,0.657458174753205,0.657458174753205,0.606847651152468,0.544701807821366,0.544701807821366,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9018677",0.607271849402404,"Biosynthesis of DHA-derived SPMs",0.448944218623103,0.448077219878038,0.505757808872709,0.549961203901445,0.496746453501941,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-74751",0.607271849402404,"Insulin receptor signalling cascade",0.323407703879037,0.602404733911731,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-74752",0.607271849402404,"Signaling by Insulin receptor",0.323407703879037,0.602404733911731,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1834949",0.607271849402404,"Cytosolic sensors of pathogen-associated DNA ",0.703070876550655,0.626474633947663,0.505757808872709,0.325012742538874,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9018678",0.607271849402404,"Biosynthesis of specialized proresolving mediators (SPMs)",0.474080922689698,0.503941910247926,0.505757808872709,0.549961203901445,0.496746453501941,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168638",0.607271849402404,"NOD1/2 Signaling Pathway",0.638892966796051,0.602404733911731,0.505757808872709,0.325012742538874,0.444599574854398,0.536546060717068,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-166058",0.607271849402404,"MyD88:MAL(TIRAP) cascade initiated on plasma membrane",0.474080922689698,0.602404733911731,0.505757808872709,0.368903312637169,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168179",0.607271849402404,"Toll Like Receptor TLR1:TLR2 Cascade",0.474080922689698,0.602404733911731,0.505757808872709,0.368903312637169,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168188",0.607271849402404,"Toll Like Receptor TLR6:TLR2 Cascade",0.474080922689698,0.602404733911731,0.505757808872709,0.368903312637169,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-181438",0.607271849402404,"Toll Like Receptor 2 (TLR2) Cascade",0.474080922689698,0.602404733911731,0.505757808872709,0.368903312637169,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-190236",0.607271849402404,"Signaling by FGFR",0.38224433575471,0.632154668683662,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-198753",0.607271849402404,"ERK/MAPK targets",0.38224433575471,0.602404733911731,0.735981920956751,0.549961203901445,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-425393",0.607271849402404,"Transport of inorganic cations/anions and amino acids/oligopeptides",0.613468190950107,0.602404733911731,0.505757808872709,0.325012742538874,0.36185792952012,0.2964626986253,0.089667038957883,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8939243",0.607271849402404,"RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known",0.38224433575471,0.404112818780624,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168138",0.607271849402404,"Toll Like Receptor 9 (TLR9) Cascade",0.502294618532516,0.602404733911731,0.670079175874988,0.368903312637169,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3700989",0.607271849402404,"Transcriptional Regulation by TP53",0.38224433575471,0.404112818780624,0.505757808872709,0.193497145059222,0.3371369955999,0.2964626986253,0.089667038957883,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,0.3630621942192,0.25574483416521,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1592389",0.607271849402404,"Activation of Matrix Metalloproteinases",0.474080922689698,0.602404733911731,0.670079175874988,0.62495086677817,0.550445999316192,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3371556",0.607271849402404,"Cellular response to heat stress",0.38224433575471,0.448077219878038,0.670079175874988,0.399395412724773,0.477445962211958,0.546029695356119,0.362277746159708,0.321386874472306,0.321386874472306,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-400253",0.607271849402404,"Circadian Clock",0.38224433575471,0.448077219878038,0.670079175874988,0.399395412724773,0.477445962211958,0.546029695356119,0.362277746159708,0.321386874472306,0.321386874472306,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-109704",0.607271849402404,"PI3K Cascade",0.38224433575471,0.632794438949397,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-450282",0.607271849402404,"MAPK targets/ Nuclear events mediated by MAP kinases",0.38224433575471,0.572631206753357,0.52260629047387,0.333723101231822,0.50137523917072,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9024446",0.607271849402404,"NR1H2 and NR1H3-mediated signaling",0.549705634355688,0.572631206753357,0.52260629047387,0.333723101231822,0.50137523917072,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2559583",0.607271849402404,"Cellular Senescence",0.38224433575471,0.602404733911731,0.68413686019316,0.375738613257873,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-166166",0.607271849402404,"MyD88-independent TLR4 cascade ",0.549705634355688,0.642401185487417,0.689228869926382,0.383690200195311,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-937061",0.607271849402404,"TRIF(TICAM1)-mediated TLR4 signaling ",0.549705634355688,0.642401185487417,0.689228869926382,0.383690200195311,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-211981",0.607271849402404,"Xenobiotics",0.38224433575471,0.404112818780624,0.505757808872709,0.549961203901445,0.496746453501941,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-381119",0.607271849402404,"Unfolded Protein Response (UPR)",0.38224433575471,0.404112818780624,0.505757808872709,0.325012742538874,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-112399",0.607271849402404,"IRS-mediated signalling",0.38224433575471,0.642401185487417,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-166016",0.607271849402404,"Toll Like Receptor 4 (TLR4) Cascade",0.502294618532516,0.624100297502391,0.557657971652884,0.49546510753325,0.504472625790053,0.607400883505279,0.447106366166497,0.362082359474094,0.362082359474094,0.323589567129998,0.292057279826203,0.292057279826203,0.282134563925389,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168142",0.607271849402404,"Toll Like Receptor 10 (TLR10) Cascade",0.613468190950107,0.607676706281574,0.629087596816081,0.355605895884058,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168176",0.607271849402404,"Toll Like Receptor 5 (TLR5) Cascade",0.613468190950107,0.607676706281574,0.629087596816081,0.355605895884058,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-975871",0.607271849402404,"MyD88 cascade initiated on plasma membrane",0.613468190950107,0.607676706281574,0.629087596816081,0.355605895884058,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-211897",0.607271849402404,"Cytochrome P450 - arranged by substrate type",0.38224433575471,0.503941910247926,0.689228869926382,0.630576518599858,0.564137241166771,0.546029695356119,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9006936",0.607271849402404,"Signaling by TGF-beta family members",0.703070876550655,0.779116397297682,0.689228869926382,0.428607149480586,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1852241",0.607271849402404,"Organelle biogenesis and maintenance",0.422620292899137,0.503941910247926,0.505757808872709,0.247483336030452,0.36185792952012,0.49751781997298,0.316615292510041,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,0.198660005893745,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3247509",0.607271849402404,"Chromatin modifying enzymes",0.613225788135337,0.602404733911731,0.505757808872709,0.399395412724773,0.496746453501941,0.586610678167411,0.413374954421778,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-4839726",0.607271849402404,"Chromatin organization",0.613225788135337,0.602404733911731,0.505757808872709,0.399395412724773,0.496746453501941,0.586610678167411,0.413374954421778,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-448424",0.607271849402404,"Interleukin-17 signaling",0.474080922689698,0.602404733911731,0.52260629047387,0.325012742538874,0.496746453501941,0.558507976029297,0.401732815863968,0.32597809305096,0.32597809305096,0.299908203871532,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-450294",0.607271849402404,"MAP kinase activation",0.474080922689698,0.602404733911731,0.52260629047387,0.325012742538874,0.496746453501941,0.558507976029297,0.401732815863968,0.32597809305096,0.32597809305096,0.299908203871532,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-198725",0.607271849402404,"Nuclear Events (kinase and transcription factor activation)",0.396600365786232,0.602404733911731,0.735981920956751,0.549961203901445,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3781865",0.607271849402404,"Diseases of glycosylation",0.638892966796051,0.787601395385354,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,0.141192431845409,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5668599",0.607271849402404,"RHO GTPases Activate NADPH Oxidases",0.396600365786232,0.446324690269869,0.735981920956751,0.549961203901445,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-68875",0.607271849402404,"Mitotic Prophase",0.396600365786232,0.446324690269869,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-881907",0.607271849402404,"Gastrin-CREB signalling pathway via PKC and MAPK",0.396600365786232,0.602404733911731,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2404192",0.607271849402404,"Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)",0.38224433575471,0.647766160394693,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2428924",0.607271849402404,"IGF1R signaling cascade",0.38224433575471,0.647766160394693,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2428928",0.607271849402404,"IRS-related events triggered by IGF1R",0.38224433575471,0.647766160394693,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2559582",0.607271849402404,"Senescence-Associated Secretory Phenotype (SASP)",0.38224433575471,0.602404733911731,0.735981920956751,0.572066065591731,0.510316189657135,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5633007",0.607271849402404,"Regulation of TP53 Activity",0.38224433575471,0.175554186003043,0.505757808872709,0.139714834858725,0.3371369955999,0.2964626986253,0.0783732769657476,0.314120396090151,0.314120396090151,0.230944820756852,0.252923248911029,0.252923248911029,0.282134563925389,0.198660005893745,NA,NA,NA,NA,NA,NA,NA
"R-HSA-373760",0.607271849402404,"L1CAM interactions",0.38224433575471,0.602404733911731,0.743156575312454,0.563519583972045,0.496746453501941,0.586610678167411,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-166520",0.607271849402404,"Signaling by NTRKs",0.638892966796051,0.779116397297682,0.735981920956751,0.549961203901445,0.683959642022813,0.582605465947298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9006931",0.607271849402404,"Signaling by Nuclear Receptors",0.448944218623103,0.602404733911731,0.629087596816081,0.560475671143575,0.640211415303729,0.687204236666755,0.531436635032971,0.440090265085792,0.440090265085792,0.395465432814633,0.342788073866405,0.342788073866405,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8957322",0.607271849402404,"Metabolism of steroids",0.613468190950107,0.606530847945287,0.751882070481952,0.810276703260632,0.726304260853926,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-109606",0.607271849402404,"Intrinsic Pathway for Apoptosis",0.80598480061014,0.669303135578496,0.735981920956751,0.572985684403408,0.515355219135744,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2122947",0.607271849402404,"NOTCH1 Intracellular Domain Regulates Transcription",0.621984214272921,0.602404733911731,0.505757808872709,0.325012742538874,0.423748184638223,0.499752197688609,0.334633963202609,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2426168",0.607271849402404,"Activation of gene expression by SREBF (SREBP)",0.621984214272921,0.669303135578496,0.735981920956751,0.572985684403408,0.515355219135744,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3371571",0.607271849402404,"HSF1-dependent transactivation",0.422620292899137,0.607676706281574,0.505757808872709,0.325012742538874,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-450302",0.607271849402404,"activated TAK1 mediates p38 MAPK activation",0.6539092745197,0.607676706281574,0.505757808872709,0.325012742538874,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-450321",0.607271849402404,"JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1",0.6539092745197,0.607676706281574,0.505757808872709,0.325012742538874,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5654738",0.607271849402404,"Signaling by FGFR2",0.422620292899137,0.793185722856077,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5654743",0.607271849402404,"Signaling by FGFR4",0.422620292899137,0.607676706281574,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5674400",0.607271849402404,"Constitutive Signaling by AKT1 E17K in Cancer",0.6539092745197,0.607676706281574,0.505757808872709,0.325012742538874,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9029569",0.607271849402404,"NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux",0.422620292899137,0.448077219878038,0.505757808872709,0.325012742538874,0.496746453501941,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9018519",0.607271849402404,"Estrogen-dependent gene expression",0.38224433575471,0.626474633947663,0.735981920956751,0.478375530866182,0.496746453501941,0.546029695356119,0.362277746159708,0.321386874472306,0.321386874472306,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1280215",0.620915922006567,"Cytokine Signaling in Immune system",0.6539092745197,0.813090025750308,0.829964223908834,0.626262333515219,0.84424579527303,0.781788396738593,0.849758348132699,0.751036741323403,0.751036741323403,0.702501027479882,0.644995937025672,0.644995937025672,0.639956880963268,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168181",0.620915922006567,"Toll Like Receptor 7/8 (TLR7/8) Cascade",0.638892966796051,0.632154668683662,0.670079175874988,0.368903312637169,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-975138",0.620915922006567,"TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation",0.638892966796051,0.632154668683662,0.670079175874988,0.368903312637169,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-975155",0.620915922006567,"MyD88 dependent cascade initiated on endosome",0.638892966796051,0.632154668683662,0.670079175874988,0.368903312637169,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1655829",0.63184307338582,"Regulation of cholesterol biosynthesis by SREBP (SREBF)",0.638892966796051,0.711944797427225,0.743156575312454,0.585699523669021,0.519771802588038,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168164",0.642721941922778,"Toll Like Receptor 3 (TLR3) Cascade",0.651053061458746,0.632794438949397,0.670079175874988,0.368903312637169,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-187687",0.642721941922778,"Signalling to ERKs",0.448944218623103,0.448077219878038,0.505757808872709,0.325012742538874,0.496746453501941,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5617472",0.642721941922778,"Activation of anterior HOX genes in hindbrain development during early embryogenesis",0.448944218623103,0.448077219878038,0.505757808872709,0.325012742538874,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5619507",0.642721941922778,"Activation of HOX genes during differentiation",0.448944218623103,0.448077219878038,0.505757808872709,0.325012742538874,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6794362",0.642721941922778,"Protein-protein interactions at synapses",0.878266730186168,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8939211",0.648331082977025,"ESR-mediated signaling",0.474080922689698,0.607676706281574,0.767540541235855,0.572985684403408,0.50137523917072,0.602109580696321,0.438523375572866,0.354813297936685,0.354813297936685,0.323589567129998,0.289254777755047,0.289254777755047,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1442490",0.667020670733573,"Collagen degradation",0.638892966796051,0.602404733911731,0.646273212895212,0.368903312637169,0.444599574854398,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1474244",0.693526278443396,"Extracellular matrix organization",0.80598480061014,0.813090025750308,0.735981920956751,0.686848666808386,0.574219363551304,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-373752",0.706208410752061,"Netrin-1 signaling",0.474080922689698,0.626474633947663,0.505757808872709,0.325012742538874,0.496746453501941,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3928663",0.706208410752061,"EPHA-mediated growth cone collapse",0.703070876550655,0.626474633947663,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-442742",0.706208410752061,"CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling",0.703070876550655,0.813090025750308,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1266738",0.70950228127872,"Developmental Biology",0.396600365786232,0.607676706281574,0.735981920956751,0.549961203901445,0.603988997130657,0.611052259274509,0.853344285271607,0.75812636348317,0.75812636348317,0.710440624261716,0.653635148160053,0.653635148160053,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2219528",0.720404009587747,"PI3K/AKT Signaling in Cancer",0.613468190950107,0.766373543293449,0.735981920956751,0.549961203901445,0.67766508960736,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-73894",0.720404009587747,"DNA Repair",0.703070876550655,0.766373543293449,0.735981920956751,0.549961203901445,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-445144",0.774164306410579,"Signal transduction by L1",0.502294618532516,0.519959112004246,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-445989",0.774164306410579,"TAK1 activates NFkB by phosphorylation and activation of IKKs complex",0.892781997949782,0.82415817112908,0.735981920956751,0.549961203901445,0.500734797437006,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-449147",0.826746820636846,"Signaling by Interleukins",0.703070876550655,0.820471321617344,0.751882070481952,0.585686129122768,0.871121935492728,0.885436106359969,0.775448572536672,0.657458174753205,0.657458174753205,0.606847651152468,0.544701807821366,0.544701807821366,0.543041585514887,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168928",0.844023587078035,"DDX58/IFIH1-mediated induction of interferon-alpha/beta",0.733165660296535,0.632794438949397,0.52260629047387,0.333723101231822,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-212165",0.844023587078035,"Epigenetic regulation of gene expression",0.733165660296535,0.632794438949397,0.735981920956751,0.563519583972045,0.50137523917072,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5576892",0.844023587078035,"Phase 0 - rapid depolarisation",0.549705634355688,0.632794438949397,0.52260629047387,0.333723101231822,0.36185792952012,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-187037",0.844023587078035,"Signaling by NTRK1 (TRKA)",0.646302746143876,0.647766160394693,0.735981920956751,0.549961203901445,0.640211415303729,0.558507976029297,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3928665",0.864066080913395,"EPH-ephrin mediated repulsion of cells",0.856872526210604,0.779116397297682,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-195258",0.864066080913395,"RHO GTPase Effectors",0.613468190950107,0.602404733911731,0.629087596816081,0.62495086677817,0.774405439118033,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-112409",0.864066080913395,"RAF-independent MAPK1/3 activation",0.613468190950107,0.779116397297682,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-156580",0.864066080913395,"Phase II - Conjugation of compounds",0.613468190950107,0.779116397297682,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1679131",0.864066080913395,"Trafficking and processing of endosomal TLR",0.613468190950107,0.779116397297682,0.735981920956751,0.549961203901445,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1912408",0.864066080913395,"Pre-NOTCH Transcription and Translation",0.613468190950107,0.602404733911731,0.505757808872709,0.325012742538874,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2022090",0.864066080913395,"Assembly of collagen fibrils and other multimeric structures",0.613468190950107,0.779116397297682,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5250941",0.864066080913395,"Negative epigenetic regulation of rRNA expression",0.856872526210604,0.779116397297682,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8864260",0.864066080913395,"Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors",0.613468190950107,0.602404733911731,0.505757808872709,0.325012742538874,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9609507",0.864066080913395,"Protein localization",0.856872526210604,0.779116397297682,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2644602",0.864066080913395,"Signaling by NOTCH1 PEST Domain Mutants in Cancer",0.703070876550655,0.607676706281574,0.505757808872709,0.325012742538874,0.493948230420621,0.546029695356119,0.362277746159708,0.321386874472306,0.321386874472306,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2644603",0.864066080913395,"Signaling by NOTCH1 in Cancer",0.703070876550655,0.607676706281574,0.505757808872709,0.325012742538874,0.493948230420621,0.546029695356119,0.362277746159708,0.321386874472306,0.321386874472306,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2644606",0.864066080913395,"Constitutive Signaling by NOTCH1 PEST Domain Mutants",0.703070876550655,0.607676706281574,0.505757808872709,0.325012742538874,0.493948230420621,0.546029695356119,0.362277746159708,0.321386874472306,0.321386874472306,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2894858",0.864066080913395,"Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer",0.703070876550655,0.607676706281574,0.505757808872709,0.325012742538874,0.493948230420621,0.546029695356119,0.362277746159708,0.321386874472306,0.321386874472306,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2894862",0.864066080913395,"Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants",0.703070876550655,0.607676706281574,0.505757808872709,0.325012742538874,0.493948230420621,0.546029695356119,0.362277746159708,0.321386874472306,0.321386874472306,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1483255",0.86889855822769,"PI Metabolism",0.613468190950107,0.647766160394693,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9614085",0.86889855822769,"FOXO-mediated transcription",0.613468190950107,0.602404733911731,0.591798992931181,0.356585331981723,0.413181553612532,0.499752197688609,0.331231338395074,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-422475",0.86889855822769,"Axon guidance",0.613225788135337,0.779116397297682,0.867201610434087,0.74787686168301,0.726304260853926,0.661519521946481,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-196854",0.86889855822769,"Metabolism of vitamins and cofactors",0.687662687224028,0.602404733911731,0.735981920956751,0.74787686168301,0.661941067525147,0.582605465947298,0.411917625254977,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-194315",0.86889855822769,"Signaling by Rho GTPases",0.621984214272921,0.602404733911731,0.646273212895212,0.626262333515219,0.780523897457144,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1980143",0.86889855822769,"Signaling by NOTCH1",0.703070876550655,0.626474633947663,0.505757808872709,0.325012742538874,0.496746453501941,0.546029695356119,0.362277746159708,0.321386874472306,0.321386874472306,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5693532",0.86889855822769,"DNA Double-Strand Break Repair",0.703070876550655,0.779116397297682,0.794791309573706,0.649146897358914,0.577066903036611,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1474290",0.86889855822769,"Collagen formation",0.638892966796051,0.779116397297682,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-162599",0.86889855822769,"Late Phase of HIV Life Cycle",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1912422",0.86889855822769,"Pre-NOTCH Expression and Processing",0.638892966796051,0.602404733911731,0.505757808872709,0.325012742538874,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2029482",0.86889855822769,"Regulation of actin dynamics for phagocytic cup formation",0.638892966796051,0.779116397297682,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-204998",0.86889855822769,"Cell death signalling via NRAGE, NRIF and NADE",0.856872526210604,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2173793",0.86889855822769,"Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer",0.856872526210604,0.779116397297682,0.735981920956751,0.549961203901445,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5625740",0.86889855822769,"RHO GTPases activate PKNs",0.638892966796051,0.779116397297682,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-622312",0.86889855822769,"Inflammasomes",0.856872526210604,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6785807",0.871986197481828,"Interleukin-4 and Interleukin-13 signaling",0.80598480061014,0.779116397297682,0.913969224170398,0.790785221397698,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2682334",0.883542486931886,"EPH-Ephrin signaling",0.925459595693906,0.83611759121255,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-170834",0.890094706828457,"Signaling by TGF-beta Receptor Complex",0.80598480061014,0.852625417907052,0.735981920956751,0.572985684403408,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1428517",0.899997111621759,"The citric acid (TCA) cycle and respiratory electron transport",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-177929",0.899997111621759,"Signaling by EGFR",0.638892966796051,0.787601395385354,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-186712",0.899997111621759,"Regulation of beta-cell development",0.638892966796051,0.602404733911731,0.505757808872709,0.325012742538874,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3371453",0.899997111621759,"Regulation of HSF1-mediated heat shock response",0.638892966796051,0.602404733911731,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5674135",0.899997111621759,"MAP2K and MAPK activation",0.638892966796051,0.602404733911731,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5693607",0.899997111621759,"Processing of DNA double-strand break ends",0.638892966796051,0.602404733911731,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5696398",0.899997111621759,"Nucleotide Excision Repair",0.856872526210604,0.787601395385354,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6802948",0.899997111621759,"Signaling by high-kinase activity BRAF mutants",0.638892966796051,0.602404733911731,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9006115",0.899997111621759,"Signaling by NTRK2 (TRKB)",0.856872526210604,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9008059",0.899997111621759,"Interleukin-37 signaling",0.638892966796051,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3108232",0.914600314168922,"SUMO E3 ligases SUMOylate target proteins",0.6539092745197,0.632154668683662,0.735981920956751,0.527153175673921,0.510316189657135,0.610915358920212,0.455344650688916,0.36908951056247,0.36908951056247,0.330022786987757,0.297947138355282,0.297947138355282,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2559580",0.947555268600605,"Oxidative Stress Induced Senescence",0.764393142559572,0.632794438949397,0.735981920956751,0.537179952048922,0.603988997130657,0.553376238908736,0.39132628290722,0.325042388920091,0.325042388920091,0.292849304840985,0.271737675382429,0.271737675382429,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-390466",0.959392326418766,"Chaperonin-mediated protein folding",0.638892966796051,0.732427463073306,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-391251",0.959392326418766,"Protein folding",0.638892966796051,0.732427463073306,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-211976",0.959392326418766,"Endogenous sterols",0.6539092745197,0.793185722856077,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5654736",0.959392326418766,"Signaling by FGFR1",0.6539092745197,0.793185722856077,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5654741",0.959392326418766,"Signaling by FGFR3",0.6539092745197,0.793185722856077,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1483257",0.988681346666156,"Phospholipid metabolism",0.627322214341634,0.624100297502391,0.897745917805963,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1430728",0.988681346666156,"Metabolism",0.717515333054073,0.607676706281574,0.735981920956751,0.896659084166421,0.829408978860103,0.871725329824347,0.849758348132699,0.918753181081572,0.918753181081572,0.888709176680782,0.847593400287849,0.847593400287849,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2990846",0.992937217089029,"SUMOylation",0.687662687224028,0.632794438949397,0.735981920956751,0.549961203901445,0.515355219135744,0.619577306475659,0.464858021662769,0.376343815988835,0.376343815988835,0.333962911531821,0.301480410916096,0.301480410916096,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-381426",0.992937217089029,"Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)",0.856872526210604,0.857188988792508,0.760225314802227,0.619884081441139,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-162587",0.998277036956373,"HIV Life Cycle",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-165159",0.998277036956373,"mTOR signalling",0.687662687224028,0.607676706281574,0.505757808872709,0.325012742538874,0.36185792952012,0.2964626986253,0.105101971371931,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,0.141192431845409,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9012852",0.998277036956373,"Signaling by NOTCH3",0.687662687224028,0.607676706281574,0.505757808872709,0.325012742538874,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-442755",0.998277036956373,"Activation of NMDA receptors and postsynaptic events",0.856872526210604,0.810464133654136,0.755523859380735,0.571320549541921,0.500734797437006,0.49751781997298,0.316615292510041,0.35113134116845,0.35113134116845,0.320724590233591,0.286251919801392,0.286251919801392,0.278778873757222,0.198660005893745,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9006934",0.998277036956373,"Signaling by Receptor Tyrosine Kinases",0.638892966796051,0.747238738120207,0.751882070481952,0.62495086677817,0.820172393054832,0.607400883505279,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168256",0.998277036956373,"Immune System",0.856872526210604,0.907774608259056,0.887313131135493,0.563519583972045,0.829962281238915,0.719391542985198,0.849758348132699,0.699830651998688,0.699830651998688,0.620675327145308,0.536354852123958,0.536354852123958,0.794211148341047,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-112310",0.999822648725816,"Neurotransmitter release cycle",0.882490654579793,0.813090025750308,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,0.316615292510041,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1226099",0.999822648725816,"Signaling by FGFR in disease",0.703070876550655,0.813090025750308,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5621575",0.999822648725816,"CD209 (DC-SIGN) signaling",0.703070876550655,0.626474633947663,0.505757808872709,0.325012742538874,0.36185792952012,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2262752",0.999822648725816,"Cellular responses to stress",0.6539092745197,0.669303135578496,0.735981920956751,0.549961203901445,0.496746453501941,0.594665754415345,0.411917625254977,0.325042388920091,0.325042388920091,0.283840342337004,0.252923248911029,0.252923248911029,0.485987700321506,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8953897",0.999822648725816,"Cellular responses to external stimuli",0.6539092745197,0.669303135578496,0.735981920956751,0.549961203901445,0.496746453501941,0.594665754415345,0.411917625254977,0.325042388920091,0.325042388920091,0.283840342337004,0.252923248911029,0.252923248911029,0.485987700321506,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1433557",0.999822648725816,"Signaling by SCF-KIT",0.687662687224028,0.779116397297682,0.68413686019316,0.62495086677817,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-196849",0.999822648725816,"Metabolism of water-soluble vitamins and cofactors",0.687662687224028,0.607676706281574,0.769414504988952,0.62495086677817,0.553296973117084,0.546029695356119,0.362277746159708,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-68877",0.999822648725816,"Mitotic Prometaphase",0.6539092745197,0.602404733911731,0.871956816928158,0.730587396211608,0.646324924804239,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-392499",0.999822648725816,"Metabolism of proteins",0.725008084080951,0.780006841103493,0.769414504988952,0.549961203901445,0.701169351183535,0.858081631796936,0.675433237248052,0.500704128967612,0.500704128967612,0.425105307878771,0.343716518958479,0.343716518958479,0.648872192475843,0.456586244382527,NA,NA,NA,NA,NA,NA,NA
"R-HSA-15869",0.999822648725816,"Metabolism of nucleotides",0.856872526210604,0.779116397297682,0.782858147010773,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-913531",0.999822648725816,"Interferon Signaling",0.856872526210604,0.873060325737462,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2565942",0.999822648725816,"Regulation of PLK1 Activity at G2/M Transition",0.703070876550655,0.632154668683662,0.735981920956751,0.549961203901445,0.500734797437006,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5628897",0.999822648725816,"TP53 Regulates Metabolic Genes",0.703070876550655,0.632154668683662,0.52260629047387,0.333723101231822,0.36185792952012,0.2964626986253,0.105101971371931,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,0.141192431845409,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5693567",0.999822648725816,"HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)",0.703070876550655,0.632154668683662,0.735981920956751,0.549961203901445,0.500734797437006,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6804757",0.999822648725816,"Regulation of TP53 Degradation",0.703070876550655,0.632154668683662,0.735981920956751,0.549961203901445,0.500734797437006,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6806003",0.999822648725816,"Regulation of TP53 Expression and Degradation",0.703070876550655,0.632154668683662,0.735981920956751,0.549961203901445,0.500734797437006,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8853659",0.999822648725816,"RET signaling",0.703070876550655,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-453274",0.999822648725816,"Mitotic G2-G2/M phases",0.703070876550655,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,0.661519521946481,0.502910292207946,0.414195383793154,0.414195383793154,0.37210906863266,0.328555532330068,0.328555532330068,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69275",0.999822648725816,"G2/M Transition",0.703070876550655,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,0.661519521946481,0.502910292207946,0.414195383793154,0.414195383793154,0.37210906863266,0.328555532330068,0.328555532330068,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6811558",0.999822648725816,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",0.687662687224028,0.829797015345073,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2029480",0.999822648725816,"Fcgamma receptor (FCGR) dependent phagocytosis",0.703070876550655,0.874615139366,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2219530",0.999822648725816,"Constitutive Signaling by Aberrant PI3K in Cancer",0.703070876550655,0.874615139366,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-350054",0.999822648725816,"Notch-HLH transcription pathway",0.733165660296535,0.632794438949397,0.52260629047387,0.333723101231822,0.50137523917072,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-375165",0.999822648725816,"NCAM signaling for neurite out-growth",0.733165660296535,0.632794438949397,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-76009",0.999822648725816,"Platelet Aggregation (Plug Formation)",0.733165660296535,0.632794438949397,0.52260629047387,0.333723101231822,0.36185792952012,0.2964626986253,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,0.141192431845409,0.0343434343434345,0.0343434343434345,0.0343434343434345,0.0343434343434345,0.0343434343434345,0.0343434343434345,0.0343434343434345
"R-HSA-383280",0.999822648725816,"Nuclear Receptor transcription pathway",0.856872526210604,0.732427463073306,0.735981920956751,0.755596187634501,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5688426",0.999822648725816,"Deubiquitination",0.856872526210604,0.842167561839872,0.742697238988732,0.549961203901445,0.496746453501941,0.66521330773691,0.508154957548924,0.418921564340622,0.418921564340622,0.37655386101775,0.328555532330068,0.328555532330068,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-438064",0.999822648725816,"Post NMDA receptor activation events",0.843607498644734,0.787601395385354,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,0.316615292510041,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,0.198660005893745,NA,NA,NA,NA,NA,NA,NA
"R-HSA-168249",0.999822648725816,"Innate Immune System",0.828464066759864,0.793185722856077,0.731256160719651,0.355605895884058,0.67766508960736,0.658778174861604,0.654892855893558,0.474913272620571,0.474913272620571,0.402623893775225,0.328555532330068,0.328555532330068,0.642391149617571,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1500931",0.999822648725816,"Cell-Cell communication",0.758781681207987,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2871796",0.999822648725816,"FCERI mediated MAPK activation",0.758781681207987,0.642401185487417,0.735981920956751,0.563519583972045,0.504472625790053,0.49751781997298,0.321019869345641,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6802946",0.999822648725816,"Signaling by moderate kinase activity BRAF mutants",0.758781681207987,0.642401185487417,0.735981920956751,0.563519583972045,0.504472625790053,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6802949",0.999822648725816,"Signaling by RAS mutants",0.758781681207987,0.642401185487417,0.735981920956751,0.563519583972045,0.504472625790053,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6802955",0.999822648725816,"Paradoxical activation of RAF signaling by kinase inactive BRAF",0.758781681207987,0.642401185487417,0.735981920956751,0.563519583972045,0.504472625790053,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9649948",0.999822648725816,"Signaling downstream of RAS mutants",0.758781681207987,0.642401185487417,0.735981920956751,0.563519583972045,0.504472625790053,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-111885",0.999822648725816,"Opioid Signalling",0.874947540939653,0.780006841103493,0.804757316638534,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-597592",0.999822648725816,"Post-translational protein modification",0.856872526210604,0.83611759121255,0.735981920956751,0.549961203901445,0.510316189657135,0.711278130728442,0.502910292207946,0.376343815988835,0.376343815988835,0.323589567129998,0.275102219677884,0.275102219677884,0.589527526937353,0.423830763524971,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69278",0.999822648725816,"Cell Cycle, Mitotic",0.675689443335983,0.732427463073306,0.913969224170398,0.735291019196529,0.577066903036611,0.802517127801753,0.672927637591109,0.554802873782658,0.554802873782658,0.505150841740822,0.450480024624635,0.450480024624635,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-199418",0.999822648725816,"Negative regulation of the PI3K/AKT network",0.703070876550655,0.85121660950257,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-71387",0.999822648725816,"Metabolism of carbohydrates",0.856872526210604,0.766373543293449,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69202",0.999822648725816,"Cyclin E associated events during G1/S transition ",0.856872526210604,0.873060325737462,0.929708610141677,0.808851905192917,0.726304260853926,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-111933",0.999822648725816,"Calmodulin induced events",0.925459595693906,0.852625417907052,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-111997",0.999822648725816,"CaM pathway",0.925459595693906,0.852625417907052,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5362517",0.999822648725816,"Signaling by Retinoic Acid",0.79328944925759,0.647766160394693,0.591798992931181,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5693538",0.999822648725816,"Homology Directed Repair",0.79328944925759,0.647766160394693,0.735981920956751,0.572066065591731,0.510316189657135,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6802952",0.999822648725816,"Signaling by BRAF and RAF fusions",0.79328944925759,0.647766160394693,0.735981920956751,0.572066065591731,0.510316189657135,0.499752197688609,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1643685",0.999822648725816,"Disease",0.900510995632577,0.952558472130456,0.804757316638534,0.549961203901445,0.515355219135744,0.553376238908736,0.411917625254977,0.471640349269115,0.471640349269115,0.395465432814633,0.328555532330068,0.328555532330068,0.642391149617571,0.456586244382527,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69656",0.999822648725816,"Cyclin A:Cdk2-associated events at S phase entry",0.856872526210604,0.874615139366,0.932967473009798,0.810276703260632,0.726304260853926,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8878171",0.999822648725816,"Transcriptional regulation by RUNX1",0.80598480061014,0.813090025750308,0.887313131135493,0.686848666808386,0.574219363551304,0.661519521946481,0.502910292207946,0.414195383793154,0.414195383793154,0.37210906863266,0.328555532330068,0.328555532330068,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-212436",0.999822648725816,"Generic Transcription Pathway",0.80598480061014,0.642401185487417,0.735981920956751,0.549961203901445,0.517717889257464,0.553376238908736,0.316615292510041,0.321386874472306,0.321386874472306,0.281794291118137,0.328555532330068,0.328555532330068,0.642391149617571,0.456586244382527,NA,NA,NA,NA,NA,NA,NA
"R-HSA-73857",0.999822648725816,"RNA Polymerase II Transcription",0.80598480061014,0.647766160394693,0.735981920956751,0.549961203901445,0.519771802588038,0.553376238908736,0.316615292510041,0.321386874472306,0.321386874472306,0.281794291118137,0.328555532330068,0.328555532330068,0.642391149617571,0.456586244382527,NA,NA,NA,NA,NA,NA,NA
"R-HSA-425407",0.999822648725816,"SLC-mediated transmembrane transport",0.929310492973829,0.852625417907052,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,0.316615292510041,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,0.271399611045141,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9009391",0.999822648725816,"Extra-nuclear estrogen signaling",0.878266730186168,0.793185722856077,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-186797",0.999822648725816,"Signaling by PDGF",0.80598480061014,0.852625417907052,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6802957",0.999822648725816,"Oncogenic MAPK signaling",0.80598480061014,0.669303135578496,0.735981920956751,0.572985684403408,0.515355219135744,0.499752197688609,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-977443",0.999822648725816,"GABA receptor activation",0.80598480061014,0.852625417907052,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-112314",0.999822648725816,"Neurotransmitter receptors and postsynaptic signal transmission",0.856872526210604,0.831321710826915,0.94249974321875,0.79321131840388,0.683229578735517,0.553376238908736,0.362277746159708,0.474913272620571,0.474913272620571,0.425105307878771,0.375998025253603,0.375998025253603,0.390242210317922,0.268711540011111,NA,NA,NA,NA,NA,NA,NA
"R-HSA-112315",0.999822648725816,"Transmission across Chemical Synapses",0.87421216194311,0.83937279488528,0.905315684798773,0.704952734133476,0.556511241297879,0.49751781997298,0.316615292510041,0.543388683914395,0.543388683914395,0.494079328279748,0.439945683347022,0.439945683347022,0.454047218958092,0.308643074810583,NA,NA,NA,NA,NA,NA,NA
"R-HSA-111996",0.999822648725816,"Ca-dependent events",0.925459595693906,0.852625417907052,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-112040",0.999822648725816,"G-protein mediated events",0.925459595693906,0.852625417907052,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-112043",0.999822648725816,"PLC beta mediated events",0.925459595693906,0.852625417907052,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1489509",0.999822648725816,"DAG and IP3 signaling",0.925459595693906,0.852625417907052,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-512988",0.999822648725816,"Interleukin-3, Interleukin-5 and GM-CSF signaling",0.838615799874778,0.852625417907052,0.743156575312454,0.585699523669021,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-112316",0.999822648725816,"Neuronal System",0.856872526210604,0.876822184702723,0.94249974321875,0.790785221397698,0.656436758748128,0.499752197688609,0.316615292510041,0.594629694165444,0.594629694165444,0.544342180441138,0.488310997898972,0.488310997898972,0.486197825451133,0.345524399729924,NA,NA,NA,NA,NA,NA,NA
"R-HSA-74160",0.999822648725816,"Gene expression (Transcription)",0.843607498644734,0.669303135578496,0.743156575312454,0.549961203901445,0.534834609926941,0.558507976029297,0.316615292510041,0.325042388920091,0.325042388920091,0.281794291118137,0.329282763338106,0.329282763338106,0.642391149617571,0.456586244382527,NA,NA,NA,NA,NA,NA,NA
"R-HSA-418346",0.999822648725816,"Platelet homeostasis",0.892781997949782,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1606322",0.999822648725816,"ZBP1(DAI) mediated induction of type I IFNs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-180024",0.999822648725816,"DARPP-32 events",0.856872526210604,0.779116397297682,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1980145",0.999822648725816,"Signaling by NOTCH2",0.856872526210604,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-210990",0.999822648725816,"PECAM1 interactions",0.856872526210604,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2871809",0.999822648725816,"FCERI mediated Ca+2 mobilization",0.856872526210604,0.779116397297682,0.735981920956751,0.549961203901445,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3214842",0.999822648725816,"HDMs demethylate histones",0.856872526210604,0.779116397297682,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-418457",0.999822648725816,"cGMP effects",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5689896",0.999822648725816,"Ovarian tumor domain proteases",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5696399",0.999822648725816,"Global Genome Nucleotide Excision Repair (GG-NER)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-629594",0.999822648725816,"Highly calcium permeable postsynaptic nicotinic acetylcholine receptors",0.856872526210604,0.779116397297682,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69205",0.999822648725816,"G1/S-Specific Transcription",0.856872526210604,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-70268",0.999822648725816,"Pyruvate metabolism",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8941326",0.999822648725816,"RUNX2 regulates bone development",0.856872526210604,0.779116397297682,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-933542",0.999822648725816,"TRAF6 mediated NF-kB activation",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9616222",0.999822648725816,"Transcriptional regulation of granulopoiesis",0.856872526210604,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9617324",0.999822648725816,"Negative regulation of NMDA receptor-mediated neuronal transmission",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-982772",0.999822648725816,"Growth hormone receptor signaling",0.856872526210604,0.779116397297682,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1445148",0.999822648725816,"Translocation of SLC2A4 (GLUT4) to the plasma membrane",0.856872526210604,0.732427463073306,0.646273212895212,0.368903312637169,0.444599574854398,0.300297686482713,0.106324746821704,0.320466798440274,0.320466798440274,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,0.141192431845409,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9619483",0.999822648725816,"Activation of AMPK downstream of NMDARs",0.856872526210604,0.732427463073306,0.646273212895212,0.368903312637169,0.444599574854398,0.300297686482713,0.106324746821704,0.320466798440274,0.320466798440274,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,0.141192431845409,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5663202",0.999822648725816,"Diseases of signal transduction",0.811223825823762,0.793185722856077,0.735981920956751,0.41710113244998,0.50137523917072,0.607807177376193,0.716932583219891,0.594629694165444,0.594629694165444,0.544342180441138,0.488310997898972,0.488310997898972,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1483206",0.999822648725816,"Glycerophospholipid biosynthesis",0.856872526210604,0.76492488948708,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2187338",0.999822648725816,"Visual phototransduction",0.932479687020698,0.857188988792508,0.760225314802227,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3371497",0.999822648725816,"HSP90 chaperone cycle for steroid hormone receptors (SHR)",0.856872526210604,0.857188988792508,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9609736",0.999822648725816,"Assembly and cell surface presentation of NMDA receptors",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-73887",0.999822648725816,"Death Receptor Signalling",0.9014530366622,0.813090025750308,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5260271",0.999822648725816,"Diseases of Immune System",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5357956",0.999822648725816,"TNFR1-induced NFkappaB signaling pathway",0.856872526210604,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5602358",0.999822648725816,"Diseases associated with the TLR signaling cascade",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-622323",0.999822648725816,"Presynaptic nicotinic acetylcholine receptors",0.856872526210604,0.779116397297682,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6804760",0.999822648725816,"Regulation of TP53 Activity through Methylation",0.856872526210604,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-71406",0.999822648725816,"Pyruvate metabolism and Citric Acid (TCA) cycle",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8862803",0.999822648725816,"Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models",0.856872526210604,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8863678",0.999822648725816,"Neurodegenerative Diseases",0.856872526210604,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8936459",0.999822648725816,"RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function",0.856872526210604,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9020591",0.999822648725816,"Interleukin-12 signaling",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9634638",0.999822648725816,"Estrogen-dependent nuclear events downstream of ESR-membrane signaling",0.856872526210604,0.779116397297682,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69620",0.999822648725816,"Cell Cycle Checkpoints",0.758781681207987,0.793185722856077,0.864524715052808,0.656563732879719,0.553296973117084,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69242",0.999822648725816,"S Phase",0.869636763373911,0.917166691676094,0.94249974321875,0.830809996247415,0.756994924761345,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-193704",0.999822648725816,"p75 NTR receptor-mediated signalling",0.939591394051915,0.857188988792508,0.767540541235855,0.62495086677817,0.550445999316192,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5619102",0.999822648725816,"SLC transporter disorders",0.939591394051915,0.857188988792508,0.767540541235855,0.62495086677817,0.550445999316192,0.546029695356119,0.362277746159708,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-397014",0.999822648725816,"Muscle contraction",0.882490654579793,0.857188988792508,0.735981920956751,0.549961203901445,0.496746453501941,0.582605465947298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1640170",0.999822648725816,"Cell Cycle",0.758781681207987,0.779116397297682,0.94249974321875,0.780634625110533,0.640211415303729,0.837000490494309,0.705477328059131,0.592745557563146,0.592745557563146,0.541822063595874,0.485195410150864,0.485195410150864,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5653656",0.999822648725816,"Vesicle-mediated transport",0.874947540939653,0.779116397297682,0.602994875802337,0.333723101231822,0.496746453501941,0.303365849129404,0.106324746821704,0.314120396090151,0.314120396090151,0.331384598567734,0.299166532695814,0.299166532695814,0.282134563925389,0.198660005893745,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9607240",0.999822648725816,"FLT3 Signaling",0.856872526210604,0.862807006719994,0.982510001538153,0.917200807412265,0.865224391071406,0.711278130728442,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-181431",0.999822648725816,"Acetylcholine binding and downstream events",0.856872526210604,0.787601395385354,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2022377",0.999822648725816,"Metabolism of Angiotensinogen to Angiotensins",0.856872526210604,0.787601395385354,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3000171",0.999822648725816,"Non-integrin membrane-ECM interactions",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3295583",0.999822648725816,"TRP channels",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-354192",0.999822648725816,"Integrin alphaIIb beta3 signaling",0.856872526210604,0.787601395385354,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-438066",0.999822648725816,"Unblocking of NMDA receptors, glutamate binding and activation",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-622327",0.999822648725816,"Postsynaptic nicotinic acetylcholine receptors",0.856872526210604,0.787601395385354,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9006921",0.999822648725816,"Integrin signaling",0.856872526210604,0.787601395385354,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9022699",0.999822648725816,"MECP2 regulates neuronal receptors and channels",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9620244",0.999822648725816,"Long-term potentiation",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69615",0.999822648725816,"G1/S DNA Damage Checkpoints",0.843607498644734,0.862807006719994,0.922402195486531,0.798673276755809,0.716162313991231,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2500257",0.999822648725816,"Resolution of Sister Chromatid Cohesion",0.856872526210604,0.779116397297682,0.769414504988952,0.62495086677817,0.553296973117084,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-388841",0.999822648725816,"Costimulation by the CD28 family",0.856872526210604,0.862807006719994,0.769414504988952,0.62495086677817,0.553296973117084,0.546029695356119,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5576891",0.999822648725816,"Cardiac conduction",0.856872526210604,0.83611759121255,0.735981920956751,0.549961203901445,0.496746453501941,0.582605465947298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9006925",0.999822648725816,"Intracellular signaling by second messengers",0.856872526210604,0.810464133654136,0.975493337621477,0.879492143863145,0.930127982528842,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-380259",0.999822648725816,"Loss of Nlp from mitotic centrosomes",0.874947540939653,0.793185722856077,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-380284",0.999822648725816,"Loss of proteins required for interphase microtubule organization from the centrosome",0.874947540939653,0.793185722856077,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-447115",0.999822648725816,"Interleukin-12 family signaling",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6796648",0.999822648725816,"TP53 Regulates Transcription of DNA Repair Genes",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69231",0.999822648725816,"Cyclin D associated events in G1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69236",0.999822648725816,"G1 Phase",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-75893",0.999822648725816,"TNF signaling",0.874947540939653,0.793185722856077,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69206",0.999822648725816,"G1/S Transition",0.878266730186168,0.936246644094015,0.949261141804103,0.848721628715941,0.774405439118033,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-446652",0.999822648725816,"Interleukin-1 family signaling",0.925459595693906,0.973643513409454,0.892439385865075,0.885042319651779,0.820172393054832,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1257604",0.999822648725816,"PIP3 activates AKT signaling",0.856872526210604,0.808877514920921,0.949261141804103,0.830809996247415,0.894591761588928,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5684996",0.999822648725816,"MAPK1/MAPK3 signaling",0.856872526210604,0.930992126418092,0.979942434407614,0.904938817293898,0.843060093618597,0.68773178762458,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8986944",0.999822648725816,"Transcriptional Regulation by MECP2",0.96533670066871,0.874615139366,0.790948941053016,0.641720380611664,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3214841",0.999822648725816,"PKMTs methylate histone lysines",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-418038",0.999822648725816,"Nucleotide-like (purinergic) receptors",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-420499",0.999822648725816,"Class C/3 (Metabotropic glutamate/pheromone receptors)",0.878266730186168,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5620912",0.999822648725816,"Anchoring of the basal body to the plasma membrane",0.878266730186168,0.810464133654136,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6804758",0.999822648725816,"Regulation of TP53 Activity through Acetylation",0.878266730186168,0.810464133654136,0.735981920956751,0.549961203901445,0.496746453501941,0.49751781997298,0.316615292510041,0.314120396090151,0.314120396090151,0.281794291118137,0.252923248911029,0.252923248911029,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8854518",0.999822648725816,"AURKA Activation by TPX2",0.878266730186168,0.810464133654136,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9022692",0.999822648725816,"Regulation of MECP2 expression and activity",0.878266730186168,0.810464133654136,0.735981920956751,0.549961203901445,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-114608",0.999822648725816,"Platelet degranulation ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-380270",0.999822648725816,"Recruitment of mitotic centrosome proteins and complexes",0.882490654579793,0.813090025750308,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-380287",0.999822648725816,"Centrosome maturation",0.882490654579793,0.813090025750308,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69017",0.999822648725816,"CDK-mediated phosphorylation and removal of Cdc6",0.856872526210604,0.852625417907052,0.897745917805963,0.771106140851083,0.683229578735517,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69052",0.999822648725816,"Switching of origins to a post-replicative state",0.856872526210604,0.852625417907052,0.897745917805963,0.771106140851083,0.683229578735517,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-76002",0.999822648725816,"Platelet activation, signaling and aggregation",0.894703089574006,0.857188988792508,0.83777944258134,0.640718288250435,0.546002457123254,0.49751781997298,0.489663067398472,0.394676544403549,0.394676544403549,0.353636721506331,0.319644573695549,0.319644573695549,0.304662092580163,0.208512767715387,0.0676767676767677,0.0676767676767677,0.0676767676767677,0.0676767676767677,0.0676767676767677,0.0676767676767677,0.0676767676767677
"R-HSA-176408",0.999822648725816,"Regulation of APC/C activators between G1/S and early anaphase",0.856872526210604,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-176814",0.999822648725816,"Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins",0.856872526210604,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-187577",0.999822648725816,"SCF(Skp2)-mediated degradation of p27/p21",0.856872526210604,0.852625417907052,0.903799434236632,0.778335816295461,0.683959642022813,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-4420097",0.999822648725816,"VEGFA-VEGFR2 Pathway",0.856872526210604,0.852625417907052,0.735981920956751,0.549961203901445,0.683959642022813,0.582605465947298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-199991",0.999822648725816,"Membrane Trafficking",0.925459595693906,0.82187033123091,0.735981920956751,0.482623362457843,0.493948230420621,0.300297686482713,0.106324746821704,0.314120396090151,0.314120396090151,0.323589567129998,0.290680196332782,0.290680196332782,0.282134563925389,0.198660005893745,NA,NA,NA,NA,NA,NA,NA
"R-HSA-111465",0.999822648725816,"Apoptotic cleavage of cellular proteins",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-186763",0.999822648725816,"Downstream signal transduction",0.892781997949782,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-196071",0.999822648725816,"Metabolism of steroid hormones",0.892781997949782,0.82415817112908,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-392154",0.999822648725816,"Nitric oxide stimulates guanylate cyclase",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6806834",0.999822648725816,"Signaling by MET",0.892781997949782,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8957275",0.999822648725816,"Post-translational protein phosphorylation",0.892781997949782,0.82415817112908,0.735981920956751,0.549961203901445,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-114604",0.999822648725816,"GPVI-mediated activation cascade",0.900510995632577,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1660499",0.999822648725816,"Synthesis of PIPs at the plasma membrane",0.900510995632577,0.83611759121255,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6811434",0.999822648725816,"COPI-dependent Golgi-to-ER retrograde traffic",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-75153",0.999822648725816,"Apoptotic execution phase",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-877300",0.999822648725816,"Interferon gamma signaling",0.900510995632577,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-983189",0.999822648725816,"Kinesins",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5673001",0.999822648725816,"RAF/MAP kinase cascade",0.894703089574006,0.915167310390085,0.975493337621477,0.896659084166421,0.836757046773005,0.676525690306635,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-174143",0.999822648725816,"APC/C-mediated degradation of cell cycle proteins",0.878266730186168,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-194138",0.999822648725816,"Signaling by VEGF",0.878266730186168,0.857188988792508,0.735981920956751,0.549961203901445,0.701169351183535,0.582605465947298,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-453276",0.999822648725816,"Regulation of mitotic cell cycle",0.878266730186168,0.779116397297682,0.735981920956751,0.549961203901445,0.496746453501941,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69239",0.999822648725816,"Synthesis of DNA",0.878266730186168,0.857188988792508,0.913969224170398,0.790785221397698,0.701169351183535,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-453279",0.999822648725816,"Mitotic G1-G1/S phases",0.925459595693906,0.964659369883937,0.964008543312972,0.879492143863145,0.814729898378244,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-3928662",0.999822648725816,"EPHB-mediated forward signaling",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6783783",0.999822648725816,"Interleukin-10 signaling",0.917794153871887,0.85121660950257,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6811442",0.999822648725816,"Intra-Golgi and retrograde Golgi-to-ER traffic",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-76005",0.999822648725816,"Response to elevated platelet cytosolic Ca2+",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8856688",0.999822648725816,"Golgi-to-ER retrograde transport",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8943724",0.999822648725816,"Regulation of PTEN gene transcription",0.917794153871887,0.85121660950257,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2132295",0.999822648725816,"MHC class II antigen presentation",0.999736731043746,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9020702",0.999822648725816,"Interleukin-1 signaling",0.999736731043746,0.92241506184036,0.790948941053016,0.833906194443974,0.760746995771618,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69563",0.999822648725816,"p53-Dependent G1 DNA Damage Response",0.878266730186168,0.857188988792508,0.913969224170398,0.790785221397698,0.70419203194972,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69580",0.999822648725816,"p53-Dependent G1/S DNA damage checkpoint",0.878266730186168,0.857188988792508,0.913969224170398,0.790785221397698,0.70419203194972,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-201681",0.999822648725816,"TCF dependent signaling in response to WNT",0.878266730186168,0.779116397297682,0.794791309573706,0.619884081441139,0.515355219135744,0.616808085954792,0.463250390597046,0.375843912887359,0.375843912887359,0.332697439795313,0.300343823039495,0.300343823039495,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5683057",0.999822648725816,"MAPK family signaling cascades",0.894703089574006,0.964659369883937,0.984237451379987,0.923134881192524,0.871121935492728,0.719391542985198,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1234174",0.999822648725816,"Cellular response to hypoxia",0.96533670066871,0.857188988792508,0.735981920956751,0.549961203901445,0.496746453501941,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69306",0.999822648725816,"DNA Replication",0.882490654579793,0.857188988792508,0.918332372861127,0.79321131840388,0.710290076619477,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-451927",0.999822648725816,"Interleukin-2 family signaling",0.925459595693906,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2672351",0.999822648725816,"Stimuli-sensing channels",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-380108",0.999822648725816,"Chemokine receptors bind chemokines",0.925459595693906,0.852625417907052,0.735981920956751,0.572985684403408,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-425366",0.999822648725816,"Transport of bile salts and organic acids, metal ions and amine compounds",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-70326",0.999822648725816,"Glucose metabolism",0.925459595693906,0.852625417907052,0.735981920956751,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8856828",0.999822648725816,"Clathrin-mediated endocytosis",0.925459595693906,0.852625417907052,0.735981920956751,0.572985684403408,0.515355219135744,0.499752197688609,0.334633963202609,0.314120396090151,0.314120396090151,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-373755",0.999822648725816,"Semaphorin interactions",0.925459595693906,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-202733",0.999822648725816,"Cell surface interactions at the vascular wall",0.999736731043746,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5689880",0.999822648725816,"Ub-specific processing proteases",0.890447159334447,0.852625417907052,0.823496047286049,0.626262333515219,0.533287601274152,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-380320",0.999822648725816,"Recruitment of NuMA to mitotic centrosomes",0.929310492973829,0.857188988792508,0.751882070481952,0.603837238097875,0.533287601274152,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-4090294",0.999822648725816,"SUMOylation of intracellular receptors",0.929310492973829,0.857188988792508,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-68886",0.999822648725816,"M Phase",0.882490654579793,0.779116397297682,0.975493337621477,0.894741466855837,0.829962281238915,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1296071",0.999822648725816,"Potassium Channels",0.932479687020698,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-437239",0.999822648725816,"Recycling pathway of L1",0.932479687020698,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8878159",0.999822648725816,"Transcriptional regulation by RUNX3",0.923945699000556,0.813090025750308,0.760225314802227,0.572066065591731,0.500734797437006,0.598454340544308,0.436269168978323,0.353006574100225,0.353006574100225,0.322418034806765,0.287779290625623,0.287779290625623,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-174184",0.999822648725816,"Cdc20:Phospho-APC/C mediated degradation of Cyclin A",0.925459595693906,0.85121660950257,0.895099367737354,0.762362793899423,0.67766508960736,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-68949",0.999822648725816,"Orc1 removal from chromatin",0.925459595693906,0.85121660950257,0.895099367737354,0.762362793899423,0.67766508960736,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5663220",0.999822648725816,"RHO GTPases Activate Formins",0.939591394051915,0.857188988792508,0.767540541235855,0.62495086677817,0.550445999316192,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5621481",0.999822648725816,"C-type lectin receptors (CLRs)",0.973154109656252,0.857188988792508,0.735981920956751,0.549961203901445,0.496746453501941,0.650992938125345,0.492742627742626,0.401321101618428,0.401321101618428,0.359853770292772,0.325364833954621,0.325364833954621,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-179419",0.999822648725816,"APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint",0.929310492973829,0.852625417907052,0.897745917805963,0.770283456256544,0.683229578735517,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2980736",0.999822648725816,"Peptide hormone metabolism",0.951073160302023,0.862807006719994,0.769414504988952,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5663205",0.999822648725816,"Infectious disease",0.999736731043746,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8852276",0.999822648725816,"The role of GTSE1 in G2/M progression after G2 checkpoint",0.925459595693906,0.907774608259056,0.94249974321875,0.830809996247415,0.755706465793742,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-176409",0.999822648725816,"APC/C:Cdc20 mediated degradation of mitotic proteins",0.929310492973829,0.852625417907052,0.897745917805963,0.771106140851083,0.683229578735517,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5689603",0.999822648725816,"UCH proteinases",0.999736731043746,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6798695",0.999822648725816,"Neutrophil degranulation",0.999736731043746,0.987703199385558,0.953563003163046,0.830809996247415,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-446203",0.999822648725816,"Asparagine N-linked glycosylation",0.968264303381336,0.877648208930823,0.794791309573706,0.649146897358914,0.577066903036611,0.546029695356119,0.362277746159708,0.321386874472306,0.321386874472306,0.281794291118137,0.252923248911029,0.252923248911029,0.271399611045141,0.161073283246593,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5617833",0.999822648725816,"Cilium Assembly",0.968264303381336,0.877648208930823,0.794791309573706,0.649146897358914,0.577066903036611,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-983712",0.999822648725816,"Ion channel transport",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-109581",0.999822648725816,"Apoptosis",0.999736731043746,0.974892806517004,0.972264801414305,0.885856716268154,0.821764483711709,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-195721",0.999822648725816,"Signaling by WNT",0.927373916448774,0.82187033123091,0.895099367737354,0.702729607738286,0.577066903036611,0.661519521946481,0.502910292207946,0.414195383793154,0.414195383793154,0.37210906863266,0.328555532330068,0.328555532330068,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-418594",0.999822648725816,"G alpha (i) signalling events",0.999736731043746,0.928869158770645,0.790948941053016,0.821384153797691,0.836757046773005,0.861637980283047,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-418555",0.999822648725816,"G alpha (s) signalling events",0.999736731043746,0.987703199385558,0.949261141804103,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-157118",0.999822648725816,"Signaling by NOTCH",0.999736731043746,0.877648208930823,0.735981920956751,0.549961203901445,0.579949338150305,0.661519521946481,0.502910292207946,0.414195383793154,0.414195383793154,0.37210906863266,0.328555532330068,0.328555532330068,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2454202",0.999822648725816,"Fc epsilon receptor (FCERI) signaling",0.929310492973829,0.82415817112908,0.735981920956751,0.549961203901445,0.579949338150305,0.661519521946481,0.502910292207946,0.414195383793154,0.414195383793154,0.37210906863266,0.328555532330068,0.328555532330068,0.329747235834815,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8948751",0.999822648725816,"Regulation of PTEN stability and activity",0.960442380283953,0.857188988792508,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5357801",0.999822648725816,"Programmed Cell Death",0.999736731043746,0.976876251867625,0.974101890132365,0.890506294151955,0.828084268703416,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-983231",0.999822648725816,"Factors involved in megakaryocyte development and platelet production",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-416476",0.999822648725816,"G alpha (q) signalling events",0.925459595693906,0.979100728520894,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-9013694",0.999822648725816,"Signaling by NOTCH4",0.968264303381336,0.862807006719994,0.735981920956751,0.549961203901445,0.496746453501941,0.586610678167411,0.413374954421778,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-6807070",0.999822648725816,"PTEN Regulation",0.960442380283953,0.852625417907052,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69481",0.999822648725816,"G2/M Checkpoints",0.999736731043746,0.987703199385558,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-109582",0.999822648725816,"Hemostasis",0.999736731043746,0.987703199385558,0.988078298501649,0.917200807412265,0.842886671320659,0.645397176442335,0.748076256987174,0.62686089768369,0.62686089768369,0.576036802528569,0.518843700891699,0.518843700891699,0.516034355701728,0.363407617299552,0.107070707070707,0.107070707070707,0.107070707070707,0.107070707070707,0.107070707070707,0.107070707070707,0.107070707070707
"R-HSA-375276",0.999822648725816,"Peptide ligand-binding receptors",0.973154109656252,0.937565277889281,0.769414504988952,0.563519583972045,0.656436758748128,0.692917415593059,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-162906",0.999822648725816,"HIV Infection",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5607764",0.999822648725816,"CLEC7A (Dectin-1) signaling",0.999736731043746,0.987703199385558,0.94249974321875,0.830809996247415,0.755706465793742,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-350562",0.999822648725816,"Regulation of ornithine decarboxylase (ODC)",0.999736731043746,0.952558472130456,0.895099367737354,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8941858",0.999822648725816,"Regulation of RUNX3 expression and activity",0.999736731043746,0.952558472130456,0.895099367737354,0.761769753297466,0.67766508960736,0.582605465947298,0.411917625254977,0.337315350663875,0.337315350663875,0.307929180266523,0.275102219677884,0.275102219677884,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-174178",0.999822648725816,"APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1",0.999736731043746,0.953216800473955,0.895099367737354,0.762362793899423,0.67766508960736,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-351202",0.999822648725816,"Metabolism of polyamines",0.999736731043746,0.953216800473955,0.895099367737354,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69601",0.999822648725816,"Ubiquitin Mediated Degradation of Phosphorylated Cdc25A",0.999736731043746,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69610",0.999822648725816,"p53-Independent DNA Damage Response",0.999736731043746,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-69613",0.999822648725816,"p53-Independent G1/S DNA damage checkpoint",0.999736731043746,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5676590",0.999822648725816,"NIK-->noncanonical NF-kB signaling",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5607761",0.999822648725816,"Dectin-1 mediated noncanonical NF-kB signaling",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1234176",0.999822648725816,"Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8939902",0.999822648725816,"Regulation of RUNX2 expression and activity",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8878166",0.999822648725816,"Transcriptional regulation by RUNX2",0.999736731043746,0.987703199385558,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8953854",0.999822648725816,"Metabolism of RNA",0.999736731043746,0.987703199385558,0.949261141804103,0.851144427682529,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-8939236",0.999822648725816,"RUNX1 regulates transcription of genes involved in differentiation of HSCs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-71291",0.999822648725816,"Metabolism of amino acids and derivatives",0.999736731043746,0.94398411461349,0.949261141804103,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5668541",0.999822648725816,"TNFR2 non-canonical NF-kB pathway",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-162909",0.999822648725816,"Host Interactions of HIV factors",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-450531",0.999822648725816,"Regulation of mRNA stability by proteins that bind AU-rich elements",0.999736731043746,0.976876251867625,0.913969224170398,0.790785221397698,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-5619115",0.999822648725816,"Disorders of transmembrane transporters",0.999736731043746,0.987703199385558,0.953960319550664,0.865945946752602,0.795421555821322,0.647115711608172,0.490748646889412,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1236975",0.999822648725816,"Antigen processing-Cross presentation",0.999736731043746,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2871837",0.999822648725816,"FCERI mediated NF-kB activation",0.999736731043746,0.982337143761389,0.926190490926268,0.803884203657402,0.72181481026557,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1168372",0.999822648725816,"Downstream signaling events of B Cell Receptor (BCR)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-983169",0.999822648725816,"Class I MHC mediated antigen processing & presentation",0.999736731043746,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2467813",0.999822648725816,"Separation of Sister Chromatids",0.999736731043746,0.987703199385558,0.94249974321875,0.830809996247415,0.756994924761345,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-2555396",0.999822648725816,"Mitotic Metaphase and Anaphase",0.999736731043746,0.987703199385558,0.94249974321875,0.830809996247415,0.756994924761345,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-68882",0.999822648725816,"Mitotic Anaphase",0.999736731043746,0.987703199385558,0.94249974321875,0.830809996247415,0.756994924761345,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-983705",0.999822648725816,"Signaling by the B Cell Receptor (BCR)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-372790",0.999822648725816,"Signaling by GPCR",0.999736731043746,0.987703199385558,0.989683691427447,0.986859240106931,0.986300857694957,0.977212555751404,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-202403",0.999822648725816,"TCR signaling",0.999736731043746,0.987703199385558,0.949261141804103,0.853412365554032,0.780523897457144,0.636048701289541,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-388396",0.999822648725816,"GPCR downstream signalling",0.999736731043746,0.994222296354329,0.989174667913377,0.986859240106931,0.986300857694957,0.977212555751404,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-382551",0.999822648725816,"Transport of small molecules",0.999736731043746,0.999725604532949,0.982510001538153,0.896659084166421,0.820172393054832,0.607400883505279,0.411917625254977,0.594629694165444,0.594629694165444,0.544342180441138,0.488310997898972,0.488310997898972,0.486197825451133,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-1280218",0.999822648725816,"Adaptive Immune System",0.999736731043746,0.999806039007987,0.995408685129183,0.98528841687225,0.954713331118359,0.858081631796936,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-373076",0.999822648725816,"Class A/1 (Rhodopsin-like receptors)",0.999736731043746,0.987703199385558,0.981743159445557,0.879492143863145,0.889829460629898,0.897693111577012,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"R-HSA-500792",0.999822648725816,"GPCR ligand binding",0.999736731043746,0.997247808057947,0.989174667913377,0.917200807412265,0.930127982528842,0.928754332240929,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
